In the first half of 2020, the net profit of three listed enterprises in the chemical and pharmaceutical industry exceeded 1 billion yuan

At present, the semi-annual reports of listed companies have been published.
According to statistics, in the first half of 2020, the chemical pharmaceutical industry Shanghai and Shenzhen A-share list of listed enterprises, net profit total income of 20,236 million yuan, the top 10 enterprises including Hengrui Pharmaceuticals, Xinhecheng, Lizhu Group, Jichuan Pharmaceuticals, Health Yuan, Yuheng Pharmaceuticals, Huahai Pharmaceuticals, China Resources Shuanghe, Jindawei, Pro Pharmaceuticals.
statistics, the first half of the net profit of these ten enterprises totaled 9,965 million yuan, accounting for nearly half of the list's total net profit.
addition, the net profit of three listed companies broke 1 billion yuan, namely Hengrui Pharmaceuticals, Xinhe Cheng and Lizhu Group.
Hengrui Pharmaceutical's first half 2020 net profit: 2.662 billion yuan ranking: 1 industry one brother Hengrui Pharmaceutical in the first half of this year's economic indicators grew steadily, achieving revenue of 11.309 billion yuan, up 12.78 percent year-on-year;
the reasons for the increase in performance, Hengrui Pharmaceutical explained that mainly due to the company's innovation results and product structure optimization, the company represented by the imager non-anti-tumor products maintained a stable growth trend.
it is worth mentioning that in terms of research and development investment, Hengrui Pharmaceutical invested 1.863 billion yuan in research and development during the reporting period, up 25.56 percent year-on-year, and accounted for 16.48 percent of revenue.
company's annual research and development investment accounted for more than 10% of revenue, research and development team of more than 3,400 people.
reporting period, the company obtained 3 batches of innovative pharmaceutical preparations, 1 batch of generic pharmaceutical preparations, 37 clinical batches of innovative pharmaceuticals, 3 varieties of consistent evaluation batches, complete the consistency evaluation and declaration of 2 products.
first half of 2020 net profit: 2.212 billion yuan ranking: 2 Xin and Cheng's performance is also relatively bright, first half net profit increased 91.41 percent year-on-year.
revenue rose 36.79 percent from a year earlier, helped by higher sales prices and sales of key products.
mainly engaged in VA, VE, VD3, VH and other production.
reporting period, the company's leading products vitamin A, vitamin E, vitamin D3 sales prices and sales volume, have shown varying degrees of improvement.
addition, the nutrition business achieved sales revenue of RMB3,721 million, with sales revenue up 54.4% YoY, and the proportion of nutrition business revenue in the company's operating income increased to 70.33 percent at the end of the reporting period from 62.32 percent in the previous year.
It is worth mentioning that during the reporting period, the company also launched a comprehensive digital transformation work, identified strategic partners, started the construction of intelligent factory systems, pilot digital transformation projects;
2020 net profit: 1.005 billion yuan ranking: 3 Lizhu Group first half net profit increased 35.97 percent year-on-year.
company's five major businesses are raw materials and intermediates, digestive tract chemicals, progesterone, diagnostic reagents and equipment, Traditional Chinese medicine preparations.
, revenue from chemical agents decreased by 11.66 percent year-on-year, while API and intermediate products increased by 0.66 percent year-on-year.
For the reasons for the first half of the sales growth, the company believes that mainly due to its deepening marketing system reform, the implementation of fine management, in addition to the company's prescription drug-related products sales did not meet expectations, but due to antiviral particles and injection of sodium Aprazole increased significantly year-on-year, coupled with anti-medical reagent products to achieve new sales, to ensure the continued growth of the Group's overall performance.